Abnormal lipid levels, such as high levels of total cholesterol, low-density lipoprotein (LDL) and triglycerides and low levels of high-density lipoprotein (HDL) cholesterol, are important risk factors for coronary heart disease. There is a strong pathophysiological association of raised LDL-cholesterol with initiation and progression of coronary atherosclerosis. Robust data are available showing that lowering its levels can regress and stabilize atherosclerotic vascular disease. Dietary intervention can also reduce lipid levels in the general population and in patients with metabolic disease or coronary heart disease. Indeed, guidelines of the American Heart Association strongly suggest a lowlipid diet to prevent such diseases. 1 The World Health Organization, in the context of the Non-communicable Disease (NCD) initiative, has adopted lowering lipids as one of the nine global NCD targets to be attained by 2025. 2 Similarly, the World Heart Federation has identified high LDL levels as an area of priority action to reduce worldwide cardiovascular disease (CVD) burden. 3 An analysis of the Global Burden of Metabolic Risk Factors Study, which included 321 country-years of data from the years 1980-2008 for serum total cholesterol and 3.0 million participants, reported that cholesterol levels decreased in both sexes in the high-income countries, while they increased in low-medium income countries. 4 Notwithstanding these opposite trends, the levels of cholesterol remain always higher in high-income countries, suggesting that lifestyle policies and pharmacological interventions are still necessary in all parts of the world to improve the levels of lipids and reduce the rate of dyslipidaemia.
In their study on 3775 adults, Magriplis and co-workers 5 have reported on prevalence and awareness of dyslipidaemia, blood lipid status and treatment in Greece, a country characterized by a typical Mediterranean diet, by using data from the Hellenic Nutrition and Health Survey. Main findings were that about 21% of the population were reported as having hyperlipidaemia, 59.0% of them receiving treatment. However, only 46.6% of the treated people had a normal lipid profile and thus could be considered as being controlled. Finally, almost two-thirds of the population were unaware of their lipid status, showing that there is still room for an appropriate project of raising awareness in the population and their General Practitioners on the opportunity to control their blood lipids. The study also confirmed a direct relation between lipid status and overweight/obesity.
The picture from this Hellenic cohort is similar to that of Italy, another Mediterranean country which is also supposed to have a healthier lipid profile (as compared with Northern European countries or the USA) possibly because of the Mediterranean diet, which has lipid-lowering properties potentially leading to lower CVD risk. However, data from Italy are not so encouraging ( Table 1) . Use of lipid-lowering medications in the Moli-sani Study cohort, an adult population older than 34 years (mean age 56 AE 12 years) recruited between 2005 and 2010, was reported by 7.8% of the population (7.2% in women and 8.4% in men), while nearly 70% of the sample was diagnosed with hyperlipidaemia, of whom 11.1% were on lipidlowering treatment.
Prevalence of hypercholesterolaemia was 64.1% in the whole study sample, with slightly higher frequency in women (66.2%) as compared with men (61.8%). Hypertriglyceridaemia was present in 26.7% of the population with significant difference by gender, while over 80% of the sample was diagnosed with dyslipidaemia. Analyses by age revealed that these lipid abnormalities were generally most frequent in the 60-75 years-of-age group (Table 1) . In Italy too, 56% of the population was unaware of having high blood cholesterol and 22% did not know they had high triglyceride levels. Data from about 9000 adult Italians aged !19 years (mean age 57 AE 15 years) recruited in the Italian Nutrition & Health Survey, a telephone-based survey performed in Italy from 2010 to 2013, 6 indicated that the use of lipid-lowering medication was selfreported by 12.3% of the whole population, with no substantial differences by gender, while it progressively increased across age groups, reaching more than 20% in individuals aged ! 60 years. These studies show that in Mediterranean populations not only the prevalence of dyslipidaemia is unexpectedly high, but also its diagnosis and treatment are rather ineffective. Therefore, intensive primary and secondary prevention actions are necessary to be put in place to reverse this scenario.
Despite the limitations of its cross-sectional design, which does not allow causal inference, the study by Magriplis and colleagues re-opens the issue on whether the healthful effects of a Mediterranean diet are at least partly due to its lipid-lowering effects, a hypothesis supported by a long tradition starting with the seminal Seven Countries Study. 7 Of interest, the Greek authors found that only LDL-cholesterol levels were significantly lower in the total sample and in men reporting larger adherence to the Mediterranean diet, but not among women, while no association was found either with triglyceride levels or with HDL-cholesterol. Moreover, 50% lower odds of reporting hypercholesterolaemia were documented only among men.
From the Greek analyses, it seems that the association between Mediterranean diet and blood lipids is weaker than expected. It would be useful to recall that the term 'Mediterranean diet' indicates the traditional dietary pattern of the olive tree-growing areas of the Mediterranean basin and is characterized by daily intake of plant foods (cereals, fruits, vegetables, legumes, tree nuts, seeds and olives), olive oil as the principal source of added fat, high to moderate intake of fish and seafood, moderate consumption of poultry and dairy products (cheese and yoghurt), low consumption of red meat and moderate intake of alcohol (mainly wine) during meals. The health benefits of the Mediterranean diet are supported by several decades of literature in a variety of cultural settings, which led to its recognition as the golden standard of healthy nutrition, being strongly associated with decreased morbidity and mortality, especially from cardiovascular causes. 8 However, the pathways through which a Mediterranean diet exerts its benefits on health are still to be elucidated. Among several mechanisms, a great role has been ascribed to its lipid-lowering effect as widely discussed both in randomized clinical trials (RCTs) 9 and observational studies. Similarly, there are numerous studies showing that a Mediterranean diet, and vegetable-based diets in general, are capable of favourably impacting upon health outcomes by modulating inflammation, oxidative stress or platelet aggregation, in addition to positive effects on hormones and growth factors involved in the pathogenesis of cancer, and on gut microbiota-mediated production of metabolites influencing metabolic health, 10 or through the inhibition of oxalate generation, especially from wine. 11 An umbrella review by Dinu et al. 8 found suggestive evidence supporting the greater effectiveness of the Mediterranean diet in reducing total cholesterol, but failed to find an association between Mediterranean diet and LDL-cholesterol. Interestingly, the CARDIVEG trial 12 on 118 subjects found that a vegetarian diet was more effective in reducing LDL-cholesterol levels, whereas a Mediterranean diet led to a greater reduction in triglyceride levels with apparently no significant effects on cholesterol levels. It is worth noting that a Mediterranean diet was associated with lower levels of some inflammatory markers while a vegetarian diet was linked to increased inflammation. However, a RCT assessing the long-term effects of a Mediterranean diet in patients with type 2 diabetes found that changes in lipids were greater with the Mediterranean diet than with the low-fat diet. 13 The Moli-sani Study, analysing 1180 subjects with history of CVD, revealed an interaction between statin use and Mediterranean diet in lowering the risk of CVD mortality by 50%; of interest, the mechanisms through which the combination of drug and diet appeared to act was that of low-grade inflammation rather than a modification of the blood lipid pathway. 14 Finally, a Cochrane systematic review 15 concludes that primary prevention studies (healthy adults and adults at high risk of CVD) provided low-quality evidence for a possible small reduction in total cholesterol with low or very low quality evidence of little or no effect on LDL or HDL-cholesterol or triglycerides. Similarly, in secondary prevention (subjects with established CVD) there was low-quality evidence of little or no effect of a Mediterranean-style diet on lipid levels.
Take-home messages from the study by Magriplis and co-workers can be summarized as follows: first, blood lipid abnormalities are still largely present in a general population, also among young individuals, and there is poor awareness of it; second, in line with previous evidence, the study suggests that the lipidlowering effects of the Mediterranean diet are not so pronounced as expected, as also found in other Mediterranean settings; 14, 16 finally, more studies are needed to provide robust evidence for either the lipidlowering or the inflammatory or other pathways as the preferred mechanism(s) through which the Mediterranean diet is likely to exert its beneficial effects on health.
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